ESTRO 2024 - Abstract Book

S1206

Clinical - Head & neck

ESTRO 2024

3. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843-850. doi:10.1002/hed.20279 4. Beitler JJ, Zhang Q, Fu KK, et al. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2014;89:13-20. doi:10.1016/j.ijrobp.2013.12.027

5. Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18:1221-1237. doi:10.1016/S1470-2045(17)30458-8

6. Haussmann J, Tamaskovics B, Bölke E, et al. Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis. Hinzunahme von Chemotherapie zur hyperfraktionierten Strahlentherapie bei fortgeschrittenen malignen Kopf- und Halstumoren - eine Metaanalyse. Strahlenther Onkol. 2019;195:1041-1049. doi:10.1007/s00066-019-01511-z 7. Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012;13:145-153. doi:10.1016/S1470-2045(11)70346-1 8. Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014;32:3858-3866. doi:10.1200/JCO.2014.55.3925 9. Kiyota N, Tahara M, Mizusawa J, et al. Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II/III randomized controlled trial. J Clin Oncol. 2022;40:1980 1990. doi:10.1200/JCO.21.01293

558

Digital Poster

Impact of Immunotherapy on Overall Survival in Anaplastic Thyroid Cancer

Shikha Kini 1 , Vedat Yildiz 2 , Darrion Mitchell 3 , Emile Gogineni 3 , John Grecula 3 , David Konieczkowski 4 , Simeng Zhu 3 , Sung Jun Ma 3 , Priyanka Bhateja 3 , Dukagjin M Blakaj 3 , Vineeth Sukrithan 5 , Bhavana Konda 5 , Sujith Baliga 3 1 Crystal Springs Upland School, NA, Hillsborough, USA. 2 The Ohio State University Wexner Medical Center, Biostatistics, Columbus, USA. 3 The Ohio State University Wexner Medical Center, Radiation Oncology, Columbus, USA. 4 The Ohio State University Wexner Medical Center, Radiation Onclogy, Columbus, USA. 5 The Ohio State University Wexner Medical Center, Medical Oncology, Columbus, USA

Purpose/Objective: